Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alcohol and hepatitis C.

M Mazen Jamal1, Zainab Saadi, Timothy R Morgan

  • 1Long Beach VA Medical Center and University of California, Irvine, Long Beach, CA 90822, USA. mazen.jamal@med.va.gov

Digestive Diseases (Basel, Switzerland)
|March 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unbiased Spatial Proteomics Uncovers Hepatic in Situ Regulation in Alcohol-Associated Hepatitis.

The American journal of pathology·2026
Same author

Evidence Supporting Utility of the Oral Cholate Challenge Test of Liver Function and Physiology to Aid Clinical Management: A Review of Analytical and Clinical Validation Studies.

Gastro hep advances·2026
Same author

SIRPα Cleavage Is Associated with Inflammatory Response, Corticosteroid Nonresponse, and Worse Prognosis in Clinical and Preclinical Models of Alcohol-Associated Hepatitis.

The American journal of pathology·2026
Same author

Practice changing RCT design and rationale: Abbreviated MRI plus AFP <i>vs.</i> ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study).

JHEP reports : innovation in hepatology·2026
Same author

Rates and Factors Associated With Hepatocellular Carcinoma Diagnosis, Stage, Treatment, and Survival.

Gastro hep advances·2026
Same author

Erratum: Pilot trials of oral betaine in participants with non-alcoholic fatty liver disease and elevated alanine aminotransferase.

Hepatology (Baltimore, Md.)·2025
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Heavy alcohol consumption significantly worsens liver disease in patients with hepatitis C. Even moderate drinking can be harmful, increasing risks of fibrosis, cirrhosis, and cancer.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Toxicology

Background:

  • Alcohol use and hepatitis C are leading causes of liver injury.
  • Understanding their combined impact on liver disease is crucial.

Purpose of the Study:

  • To review the current understanding of alcohol's effects on liver disease in the context of hepatitis C.
  • To synthesize findings on the interaction between alcohol consumption and hepatitis C progression.

Main Methods:

  • Conducted a Medline database search for English articles on alcohol, hepatitis C, and liver disease.
  • Included relevant studies identified through citation searching.
  • Focused on high-quality research for the review.

Main Results:

Related Experiment Videos

  • Hepatitis C patients frequently have a history of alcohol use (up to 60%).
  • Chronic alcohol consumption (>5 drinks/day) accelerates liver fibrosis, cirrhosis, and hepatocellular carcinoma risk in hepatitis C patients.
  • Moderate alcohol intake is also detrimental, and recent use reduces interferon treatment efficacy.

Conclusions:

  • Hepatitis C and alcohol use frequently co-occur, exacerbating liver disease.
  • Heavy alcohol consumption is a significant promoter of liver disease progression in hepatitis C patients, though the exact interaction mechanism requires further study.